Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)

SHE:301281 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	265.18	178.13	325.22	148.97	66.01	37.44
Short-Term Investments	-	-	210.26	-	-	-
Trading Asset Securities	103.29	254.43	150.54	-	-	-
Cash & Short-Term Investments	368.47	432.56	686.02	148.97	66.01	37.44
Cash Growth	-28.06%	-36.95%	360.50%	125.69%	76.29%	10.48%
Accounts Receivable	102.07	95.85	75.85	56.87	43.71	66.39
Other Receivables	26.39	27.11	0.65	0.31	0.69	0.54
Receivables	128.46	122.96	76.5	57.18	44.4	66.93
Inventory	147.48	128.94	108.05	67.92	86.44	70.95
Other Current Assets	11.51	6.26	8.22	8.2	6.53	1.37
Total Current Assets	655.92	690.73	878.79	282.27	203.38	176.7
Property, Plant & Equipment	553.17	477	314.2	308.83	290.27	217.61
Long-Term Investments	192.61	190.31	184.08	-	-	-
Goodwill	1.82	1.82	-	-	-	-
Other Intangible Assets	115.36	107.17	46.02	49.08	51.76	54.76
Long-Term Deferred Tax Assets	3.3	3.06	2.92	2.09	1.62	1.69
Long-Term Deferred Charges	2.24	2.39	0.73	1.73	3.15	4.45
Other Long-Term Assets	79.91	79.98	43.22	7.79	9.34	3.33
Total Assets	1,604	1,552	1,470	651.79	559.51	458.53
Accounts Payable	37.96	42.25	50.18	54.98	60.58	28.89
Accrued Expenses	16.93	44.59	39.71	29.23	23.65	24.9
Current Income Taxes Payable	-	1.08	0	-	4.59	7.98
Current Unearned Revenue	2.61	20.24	3.5	3.02	3.09	12.75
Other Current Liabilities	42.57	11.63	17.75	20.64	18.83	25.26
Total Current Liabilities	100.07	119.78	111.14	107.86	110.75	99.79
Long-Term Debt	95.8	45.66	-	-	-	-
Long-Term Unearned Revenue	9.89	9.27	10.53	9.04	10.11	10.39
Long-Term Deferred Tax Liabilities	16.48	17.78	17.25	15.16	7.66	6.72
Other Long-Term Liabilities	-	0.38	-	-	-	-
Total Liabilities	222.24	192.87	138.93	132.06	128.52	116.9
Common Stock	108.29	108.29	108.29	58	58	58
Additional Paid-In Capital	907.67	907.67	909.97	195.34	195.34	186.45
Retained Earnings	361.29	340.26	312.3	266.2	174.93	96.75
Comprehensive Income & Other	4.08	2.57	0.48	0.19	2.72	0.43
Total Common Equity	1,381	1,359	1,331	519.73	430.98	341.63
Minority Interest	0.77	0.81	-	-	-	-
Shareholders' Equity	1,382	1,360	1,331	519.73	430.98	341.63
Total Liabilities & Equity	1,604	1,552	1,470	651.79	559.51	458.53
Total Debt	95.8	45.66	-	-	-	-
Net Cash (Debt)	272.67	386.9	686.02	148.97	66.01	37.44
Net Cash Growth	-46.77%	-43.60%	360.50%	125.69%	76.29%	-
Net Cash Per Share	2.53	3.59	6.77	1.83	0.81	0.46
Filing Date Shares Outstanding	108.28	108.29	108.29	81.2	81.2	81.2
Total Common Shares Outstanding	108.28	108.29	108.29	81.2	81.2	81.2
Working Capital	555.85	570.95	767.65	174.4	92.64	76.91
Book Value Per Share	12.76	12.55	12.29	6.40	5.31	4.21
Tangible Book Value	1,264	1,250	1,285	470.65	379.23	286.88
Tangible Book Value Per Share	11.68	11.54	11.87	5.80	4.67	3.53
Buildings	-	216.15	213.26	208.05	186.34	152.37
Machinery	-	342.54	316.21	275.82	210.37	193.11
Construction In Progress	-	183.15	12.15	19.99	66.23	22.28

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.